An FDA advisory committee's narrow July 2026 vote recommending BPC-157 for the 503A bulks list represents the primary recent catalyst for trader sentiment on a potential move to Category 1. The Pharmacy Compounding Advisory Committee approved the peptide 8-6 with one abstention, despite FDA staff concerns over limited human safety and efficacy data, over-the-counter gray-market use, and characterization issues. This followed April 2026 removal of BPC-157 from Category 2 after nomination withdrawals. However, the non-binding recommendation does not alter current status; formal placement on the Category 1 list requires FDA leadership to initiate and complete notice-and-comment rulemaking, a process that typically spans eight to twelve months with no proposed rule published as of mid-October 2026. Enforcement actions against unregulated sellers continue in parallel.